The spread of the COVID-19 virus has brought so many unexpected challenges to the life science industry and clinical trials. With events and in-person meetings moving online, trial participant numbers dropping, office spaces emptying, and some having limited access to critical resources, we’ve all had to make adjustments to our work processes and operations.

The report includes the results of our COVID-19 and TMF Management Survey, with views representing a wide range of industry stakeholders, including pharmaceutical and biotech sponsors, and CROs.

The insights inside shed light on the current challenges faced by the life science industry and what new tools, processes, and activities teams are leveraging, or can leverage, to mitigate those challenges.    

Some of the key findings: 

• 40.4% of life science teams are experiencing challenges with providing or accessing TMF content.  
  
  

• 45.2% of those that do not have an eTMF shared that their plans to implement an eTMF have risen in priority due to COVID-19. 
  
  

• 52.8% of respondents shared that they are not ready for remote inspections.